NasdaqGM:CRSP

Stock Analysis Report

Executive Summary

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases.


Snowflake Analysis

Flawless balance sheet with questionable track record.


Similar Companies

Share Price & News

How has CRISPR Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CRSP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.8%

CRSP

5.3%

US Biotechs

12.5%

US Market


1 Year Return

18.0%

CRSP

-0.7%

US Biotechs

-12.7%

US Market

Return vs Industry: CRSP exceeded the US Biotechs industry which returned -0.7% over the past year.

Return vs Market: CRSP exceeded the US Market which returned -12.7% over the past year.


Shareholder returns

CRSPIndustryMarket
7 Day5.8%5.3%12.5%
30 Day-21.8%-6.6%-14.7%
90 Day-31.3%-8.3%-21.5%
1 Year18.0%18.0%0.1%-0.7%-10.9%-12.7%
3 Year93.5%93.5%10.3%7.5%12.6%5.4%
5 Yearn/a-6.1%-10.3%31.9%17.5%

Price Volatility Vs. Market

How volatile is CRISPR Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CRISPR Therapeutics undervalued compared to its fair value and its price relative to the market?

34.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CRSP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CRSP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CRSP is poor value based on its PE Ratio (34x) compared to the Biotechs industry average (15.4x).

PE vs Market: CRSP is poor value based on its PE Ratio (34x) compared to the US market (13x).


Price to Earnings Growth Ratio

PEG Ratio: CRSP's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: CRSP is overvalued based on its PB Ratio (2.7x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is CRISPR Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

-2.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRSP's earnings are forecast to decline over the next 3 years (-2.1% per year).

Earnings vs Market: CRSP's earnings are forecast to decline over the next 3 years (-2.1% per year).

High Growth Earnings: CRSP's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CRSP's revenue (19.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CRSP's revenue (19.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRSP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CRISPR Therapeutics performed over the past 5 years?

-24.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CRSP has a large one-off gain of $16.0M impacting its December 31 2019 financial results.

Growing Profit Margin: CRSP became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: CRSP has become profitable over the past 5 years, growing earnings by -24% per year.

Accelerating Growth: CRSP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: CRSP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: CRSP's Return on Equity (7.1%) is considered low.


Next Steps

Financial Health

How is CRISPR Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CRSP's short term assets ($987.5M) exceed its short term liabilities ($57.1M).

Long Term Liabilities: CRSP's short term assets ($987.5M) exceed its long term liabilities ($70.2M).


Debt to Equity History and Analysis

Debt Level: CRSP is debt free.

Reducing Debt: CRSP currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: CRSP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CRSP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRSP is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: CRSP is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CRSP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRSP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRSP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRSP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Sam Kulkarni (40yo)

3.17s

Tenure

US$9,727,531

Compensation

Dr. Samarth Kulkarni, also known as Sam, Ph.D., serves as an Independent Director at Repare Therapeutics Inc. since December 2019. Dr Kulkarni has been the Chief Executive Officer of CRISPR Therapeutics AG ...


CEO Compensation Analysis

Compensation vs Market: Sam's total compensation ($USD9.73M) is above average for companies of similar size in the US market ($USD5.55M).

Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Rodger Novak
Founder2.25yrsUS$645.57k1.39% $35.5m
Samarth Kulkarni
CEO & Director3.17yrsUS$9.73m0.26% $6.7m
Michael Tomsicek
Chief Financial Officer2.33yrsUS$2.25mno data
James Kasinger
General Counsel & Secretary2.75yrsUS$3.16mno data
Tony Ho
Executive Vice President of Research & Development2.58yrsUS$4.15m0.075% $1.9m
Shaun Foy
no datano datano data
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datano datano data
Craig Mello
Scientific Founder & Advisory Board Memberno datano datano data
Chad Cowan
Scientific Founderno datano datano data
Matthew Porteus
Scientific Founder & Advisory Board Memberno datano datano data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Management: CRSP's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rodger Novak
Founder2.25yrsUS$645.57k1.39% $35.5m
Samarth Kulkarni
CEO & Director3.17yrsUS$9.73m0.26% $6.7m
Emmanuelle Charpentier
Co-Founder & Scientific Advisory Board Memberno datano datano data
Craig Mello
Scientific Founder & Advisory Board Memberno datano datano data
Matthew Porteus
Scientific Founder & Advisory Board Memberno datano datano data
Daniel Anderson
Scientific Founder & Advisory Board Memberno datano datano data
Ali Behbahani
Independent Director4.92yrsUS$646.79kno data
Simeon George
Independent Director4.92yrsUS$643.79kno data
Sven Lundberg
Head of Scientific Advisory Board2yrsUS$2.58mno data
John Greene
Independent Director0.75yrno datano data

2.3yrs

Average Tenure

47.5yo

Average Age

Experienced Board: CRSP's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.4%.


Top Shareholders

Company Information

CRISPR Therapeutics AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CRISPR Therapeutics AG
  • Ticker: CRSP
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.545b
  • Shares outstanding: 60.85m
  • Website: https://www.crisprtx.com

Number of Employees


Location

  • CRISPR Therapeutics AG
  • Baarerstrasse 14
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRSPNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDOct 2016
1CGDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2016
0VRQLSE (London Stock Exchange)YesCommon SharesGBUSDOct 2016

Biography

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 03:41
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.